Abstract
The pleckstrin homology (PH) domain is a versatile fold that mediates a variety of protein–protein and protein–phosphatidylinositol lipid interactions. The Ran-binding protein 2 (RanBP2) contains four interspersed Ran GTPase-binding domains (RBDn = 1–4) with close structural homology to the PH domain of Bruton's tyrosine kinase. The RBD2, kinesin-binding domain (KBD) and RBD3 comprise a tripartite domain (R2KR3) of RanBP2 that causes the unfolding, microtubule binding and biphasic activation of kinesin-1, a crucial anterograde motor of mitochondrial motility. However, the interplay between Ran GTPase and R2KR3 of RanBP2 in kinesin-1 activation and mitochondrial motility is elusive. We use structure–function, biochemical, kinetic and cell-based assays with time-lapse live-cell microscopy of over 260 000 mitochondrial-motility-related events to find mutually exclusive subdomains in RBD2 and RBD3 towards Ran GTPase binding, kinesin-1 activation and mitochondrial motility regulation. The RBD2 and RBD3 exhibit Ran-GTP-independent, subdomain and stereochemical-dependent discrimination on the biphasic kinetics of kinesin-1 activation or regulation of mitochondrial motility. Further, KBD alone and R2KR3 stimulate and suppress, respectively, multiple biophysical parameters of mitochondrial motility. The regulation of the bidirectional transport of mitochondria by either KBD or R2KR3 is highly coordinated, because their kinetic effects are accompanied always by changes in mitochondrial motile events of either transport polarity. These studies uncover novel roles in Ran GTPase-independent subdomains of RBD2 and RBD3, and KBD of RanBP2, that confer antagonizing and multi-modal mechanisms of kinesin-1 activation and regulation of mitochondrial motility. These findings open new venues towards the pharmacological harnessing of cooperative and competitive mechanisms regulating kinesins, RanBP2 or mitochondrial motility in disparate human disorders.
Keywords: kinesin, mitochondria, Ran-binding protein 2, ran GTPase
2. Introduction
Ran GTPase is a pleiotropic and master regulatory G protein switch of nucleocytoplasmic trafficking [1]. The active form of Ran GTPase, Ran-GTP, has two high-affinity targets: Ran-binding protein 1 (RanBP1) and Ran-binding protein 2 (RanBP2, also called Nup358) [2–4]. RanBP1 is an evolutionarily conserved and approximately 26 kDa single domain and cytosolic protein [2,5,6]. Conversely, RanBP2 is not evolutionarily conserved and is an approximately 358 kDa scaffold comprising four Ran GTPase-binding domains (RBDn = 1–4), which are interspersed between apparently unrelated structural and functional domains [7–9]. Prior studies support that RanBP1 and the RBDn = 1–4 of RanBP2 are structurally and biochemically alike, and present structural homology to versatile pleckstrin homology (PH) domains, such as that of the Bruton's tyrosine kinase [3,4,10–12]. In interphase cells, RanBP2 is localized among other locales at cytoplasmic filaments emanating from the nuclear pore, where it associates with nuclear import and export receptors [7,8,13,14]. Current data support that RanBP1 and the RBDn = 1–4 of RanBP2 in the presence of cytosolic and sumoylated RanGAP co-stimulate the GTPase activity of Ran GTPase bound to nuclear export receptors and cargoes upon exiting the nuclear pore [2,10,15–17]. This docking step is thought to be critical to trigger the allosteric destabilization and release of Ran GTPase, nuclear receptors and cargoes [4,11].
Several lines of evidence support that RanBP2 mediates multiple and apparently disparate cell-cycle- and cell-context-dependent processes in health and disease states. RanBP2 is implicated in nucleocytoplasmic transport [13,14,18–22], microtubule-based intracellular trafficking [23–27], viral infections by HIV-1 and adenovirus [27,28], nuclear envelope breakdown and mitosis [25,29–32], modulation of protein homeostasis by the ubiquitin–proteasome system [33,34], mitochondrial function and trafficking [24,35], regulation of protein–protein interactions and localizations by SUMOylation [17,36–38], negative regulation of cAMP signalling [39], and gene–environment interactions cross-talking to the regulation of glucose and lipid metabolism [35,40–42]. Although complex and not well understood, RanBP2's pleiotropic and cell-context-dependent properties reflect most likely combinatorial functions of (i) the association of distinct domains of RanBP2 with diverse functional factors, (ii) multi-functional properties associated to single domains of RanBP2, or (iii) cross-talk between adjacent domains of RanBP2 and its partners. For example, the RBD4 of RanBP2 was found to associate with the G protein-coupled receptor, M-opsin, an effect that is chaperoned by its adjacent cyclophilin (CY) domain. The combinatorial effect of the RBD4-CY domains promotes the production of functional M-opsin [43,44]. RanBP2 via its kinesin-binding domain (KBD) associates also with kinesin-1, a microtubule-based and anterograde dimeric motor [23,24]. The RBD2 and RBD3 of the tripartite domain, RBD2–KBD–RBD3 (R2KR3), of RanBP2 are critical to unfold kinesin-1, to relieve the inhibition of the C-terminal tail over the N-terminal motor domain of kinesin-1 and to enhance directly its microtubule-based motor activity upon activation by KBD of RanBP2 [45]. However, it is unknown whether the novel functions associated with the structural equivalent RBD2 and RBD3 reflect hitherto unappreciated intrinsic structural and functional properties harboured by these domains or extrinsic roles resulting from their association with Ran-GTP.
A diverse number of cargoes are reported to associate with kinesin-1 [46–48], but RanBP2 is the only native cargo known to activate directly the motor activity of a kinesin (kinesin-1) in a minimal reconstitution system [45]. Prior studies found that the KBD domain of RanBP2 associates directly with approximately 100 residues shared by the C-terminal tail and cargo-binding domain of two highly homologous kinesin-1 subtypes, KIF5B and KIF5C, but not KIF5A [23,24]. KIF5B and KIF5C are functionally redundant, and they are the primary motors mediating the outward (anterograde) transport of mitochondria [49–53], an effect that is affected by the ectopic cellular expression of KBD by mechanisms not understood [24]. Further, the R2KR3 of RanBP2 plays a critical role in the biphasic activation of kinesin-1 by binding to at least two cargo-binding sites in a multi-partite cargo-binding domain of each monomer of kinesin-1 tail [45]. However, the role(s) of the interplay between Ran GTPase and the RBD2 and RBD3 of R2KR3 in the regulation of kinesin-1 activation and their effect(s) on mitochondrial motility are lacking. This information is critical, because it will provide novel insights into multi-functional properties of RBD2 and RBD3, and the regulation of fast mitochondrial transport by kinesin-1. In addition, the regulations of kinesin-1 and mitochondrial motilities are also of high therapeutic value, because they play critical roles in a large number of disparate pathophysiologies lacking therapeutic approaches [54–59]. These unmet clinical needs are compounded further by the scarcity and lack of specificity of pharmacological agents towards kinesins. These pharmacological limitations arise from the non-selective, drug-mediated inhibition/targeting of the kinesin motor domains, which are highly conserved between members of the kinesin superfamily [60–63]. Hence, the understanding of the modulatory activities underlying intramolecular interactions between the poorly and highly conserved tail and motor domains of kinesins, respectively, intermolecular interactions between kinesin tails and their cargoes, or both, will aid significantly the development of therapeutic agents with high specificity and efficacy. Here, we present the most comprehensive kinetic characterization of mitochondrial motility carried out to date to uncover and correlate biochemical and biological Ran GTPase-independent, antagonizing and multi-modal properties of KBD and R2KR3 of RanBP2 towards kinesin-1 activation and regulation of various biophysical properties of mitochondrial motility.
3. Results
3.1. Mutual exclusive interactions of RBD2 and RBD3 of R2KR3 with Ran-GTP and kinesin-1
The R2KR3 and domains thereof of RanBP2 (figure 1a) affect distinct kinetic phases of KIF5B activation [45]. We examined whether Ran GTPase modulates the activation of kinesin-1 upon Ran-GTP association with the RBD2 and RBD3 of R2KR3 or these domains in R2KR3 present non-overlapping subdomains towards kinesin-1 and Ran-GTP. First, we determined the effects of increasing concentrations of Ran GTPase charged with the stable non-hydrolysable analogue of GTP, Ran-GppNHp (5′-guanosyl-[β,γ-imido]-triphospahte), on the linear rates of KIF5B activation in the absence (figure 1b) and presence of three concentrations of R2KR3 (0.05, 0.75 and 1 μM; figure 1c; see also figure 1e). Notably, Ran-GppNHp neither had an effect on the ATPase activity of KIF5B nor stimulated its activity (figure 1b). On the other hand, increasing R2KR3 concentrations promoted an increase in KIF5B activity, but its activity remained unchanged under any concentration of Ran-GppNHp tested (figure 1c). Hence, the RBD2 and RBD3 of R2KR3 present non-overlapping binding subdomains towards KIF5B and Ran-GppNHp.
To examine further the role of the interactions of RBD2 and RBD3 of R2KR3 with Ran-GTP and KIF5B, we took advantage of a mutation, W → R, identified serendipitously in the conserved ‘WKER’ motif of RBD3 of RanBP2. The atomic structure of the Ran-GppNHp-RBD1 complex [4] and structural modelling of RBDn = 2–4 of RanBP2 to RBD1 predict that the W → R mutation disrupts the association of RBDn = 1–4 with Ran-GTP (figure 1d). The WKER residues are 100 per cent conserved between RanBP1 of all species and RBDn = 1–4 of RanBP2 [4]. This motif forms electrostatic interactions with the switch I loop region (residues 29–38) of Ran-GTP, thereby preventing the intrinsic and EDTA-stimulated release of GTP from Ran-GTP [4]. In addition to destabilizing the electrostatic interactions of the WKER motif with Ran-GTP (figure 1d) [4], the bulky hydrophobic to hydrophilic residue change of W → R at the beginning of β2-sheet is predicted to cause the structural disruption (local unpacking) of neighbouring residues, because of the burying of a charged arginine residue (R) without a counter-charge in close proximity.
To validate experimentally these predictions, we first carried out pull-down assays of purified wild-type R2KR3 or mutant constructs thereof with the W2052R in RBD2 and W2349R in RBD3 upon incubation with Ran-GppNHp. As shown in figure 1e, wild-type R2KR3 co-precipitated Ran-GppNHp, whereas the counterpart mutant construct, , failed to do so at any concentrations tested. Then, to probe the unpacking effect of W → R in the RBD2 and RBD3 of on kinesin-1 activation, we compared the activation kinetics of KIF5B in the presence of R2KR3 or . We have shown previously that R2KR3 causes the biphasic kinetics of kinesin-1 activation. This activation kinetics is characterized by an initial hyperbolic (stimulatory) phase followed by a sigmoidal (cooperative) phase owing to distinct activation of binding sites in kinesin-1 tail towards selective domains of R2KR3 [45]. By using the same kinetic activation assays of kinesin-1 reported previously [45], we found that suppressed significantly the hyperbolic phase of KIF5B activation without affecting its cooperative (sigmoid) kinetic phase (figure 1f). Although not significant, this effect led also to a tenuous decrease in the ATPase activity of KIF5B (27 ± 2.6 versus 21.6 ± 3.6 s−1; figure 1f). Hence, these results further strengthen the notion that KIF5B presents multi-modal stimulatory activities. Further, the cooperative phase of KIF5B activation is not dependent on its initial hyperbolic activation phase, because the hyperbolic phase can be suppressed without impairing significantly the catalytic efficiency of KIF5B.
Finally, we probed the selectivity of R2KR3 towards its effects on the activation to two other kinesin-1 isoforms, KIF5C and KIF5A. KIF5B and KIF5C are orthologous kinesin-1 isoforms [50,51], which are known to associate specifically with RanBP2 [23,24], whereas KIF5A is implicated in distinct intracellular trafficking and disease processes [64,65], and it is thought not to associate with RanBP2 or domains therein [23,24]. As shown in figure 1g,h, R2KR3 had indistinguishable stimulatory biphasic and kinetic effects on KIF5C activity compared with KIF5B (figure 1g; compare also with figure 1f), but its stimulatory effect on KIF5A was weak and did not present a biphasic kinetics of activation (figure 1h). Hence, R2KR3 of RanBP2 is highly selective towards the highly homologous KIF5B and KIF5C isoforms.
3.2. Analyses of mitochondrial motility
Next, we examined functional relationships between the kinetics of kinesin-1 activation in the presence of KBD or R2KR3 constructs as described herein and elsewhere [45], and the regulation of fast mitochondrial transport by kinesin-1 upon ectopic expression of such constructs of RanBP2. To this effect, we used time-lapse live cell microscopy of cultured NIH-3T3 fibroblasts expressing wild-type and mutant YFP-tagged RanBP2 mini-constructs comprising KBD or R2KR3 without and with loss-of-function mutations in KBD, RBD2 or RBD3, to dissect out their effects on multiple biophysical parameters of mitochondrial motility. This kinetic analysis excluded all fission/fusion mitochondrial events (see also §5) and its primary focus was on the detection of early kinetic changes of mitochondrial motility before downstream (secondary) subcellular phenotypes ensue from sustained mitochondrial kinetic changes as reported by prior studies (figure 2) [24]. Hence, time-course-dependent studies were carried out as soon as the expression of ectopic YFP-tagged RanBP2 mini-constructs in live cells with extended protoplasmic processes and well dispersed mitochondria were detected by epifluorescence microscopy with a high-quantum efficiency CCD camera (figure 2), but not by immunoblot analyses of 1.2 million transfected cells. These analyses mitigate potential off-target effects caused by supraphysiological concentrations of RanBP2 mini-constructs and they support the validation of concentration-dependent ligand–receptor responses of kinesin-mediated mitochondrial motility upon increasing transfection times with various RanBP2 constructs. Preliminary qualitative surveys suggested that there were overall changes in mitochondrial motility between KBD and R2KR3 of RanBP2 and mock-transfected cells (figure 2a–c). Thus, we pursued in depth the quantitative and stringent examination of about 20 biophysical motility-related parameters of either polarity recorded from a large pool of motile mitochondria (more than 1800) and reflecting over 260 000 motility-related events (biophysical parameter definitions are provided in electronic supplementary material). Because the average velocity of a mitochondrion transported by microtubule-based motors ranges from 0.3 to 2.0 μm s−1 [66–68], we recorded mitochondrial motility at two frames per second, which provides the spatial resolution above that detected by our microscopy system (approx. 240 nm). This helps to exclude noise from slow actin-based transport events of mitochondria (less than 300 nm s−1) [69,70] without loss of information of fast microtubule-based transport events. Although some of the tallied biophysical motility parameters are redundant, yet confirmatory to the overall significance of the analyses performed (these are described in electronic supplementary material, figures S1 and S2), each of the biophysical parameters described in table 1 offers unique mechanist insights into critical molecular mechanisms regulating kinesin-1-mediated mitochondrial motility by various domains of RanBP2.
Table 1.
biophysical parameter | definition | significance |
---|---|---|
percentage of motile events | number of motile events recorded | overall motility behaviour |
absolute duration of pause between runs | duration of a non-motile event between two runs in the anterograde, retrograde or change of directions | regulation of kinesin or dynein motor activity from inactive to active states |
frequency of change in direction | number of times a mitochondrion changes from anterograde to retrograde direction or vice versa | regulation of cross-talk between kinesin and dynein |
motility persistency | time interval of steady movement of a mitochondrion in anterograde, retrograde or both directions | regulation of duration of motor activity of kinesin, dynein or both from active to inactive states |
mean velocity | mean velocity of all motile events in the anterograde, retrograde or both directions | mean ATPase activity of kinesin, dynein or both from several runs |
absolute velocity | velocity of a run (motile) event in the anterograde or retrograde direction | absolute ATPase (motor) activity of kinesin or dynein during a run; measures also net displacement resulting from the cooperation between motors (motor ensemble) |
3.3. Kinesin-binding domain expression causes the upregulation of mitochondrial kinetics
First, we began with the quantitative analyses of the effect of kinesin-binding domain (KBD) expression on mitochondrial motility. As shown in figure 3, we found that expression of KBD promotes changes in multiple biophysical parameters of mitochondrial motility. KBD produced a significant time-course-dependent upward shift (more than twofold) in overall mitochondrial motility (percentage of motile events; p ≤ 7.9 × 10–4). This effect was not observed with mock-transfected cells and a mutant KBD construct, KBD*, which lacks activity towards kinesin-1 binding and activation [24,45] (figure 3a; electronic supplementary material, table S1). Akin to this KBD-dependent effect, there was also a decrease in the fraction of stationary events observed (see electronic supplementary material, figure S1a). KBD, but not KBD* or mock-transfected cells, also caused a temporal decrease in pauses between anterograde runs (p ≤ 1.2 × 10−4; figure 3b; electronic supplementary material, table S2), thus supporting an upregulation of kinesin-1 activity. Notably, we found also that the duration of the pauses between consecutive runs with directionality switches were higher than the duration of pauses between runs with the same direction (p ≤ 3.2 × 10−6; figure 3c; electronic supplementary material, table S2). However, these pause events were not affected between KBD, KBD* or mock-transfected cells (data not shown), but they were accompanied by a KBD-dependent increase in the frequency of change in direction of motility (p ≤ 1.21 × 10−5; figure 3d; electronic supplementary material, table S1). These data support that KBD stimulates mitochondrial motility and the coexistence of tightly coupled and compensatory mechanisms between anterograde kinesin-1 and retrograde dynein motors in mitochondrial transport. Next, we looked at the persistence of mitochondrial motility as a functional indicator of the duration of the motor (non-stop) activity of kinesin. As shown in figure 3e, the persistence of mitochondrial anterograde motility is significantly contingent upon KBD as compared with KBD* and mock-transfected cells at every transfection time-interval (chi-squared contingency test, p < 0.001, χ2 = 39.475, Cramer's contingency coefficient ϕ = 0.631). Likewise, the persistency of anterograde motility of mitochondria in KBD-transfected cells is significantly contingent upon hours of transfection (chi-squared contingency test, p < 0.001, χ2 = 38.22, Cramer's contingency coefficient ϕ = 0.58), with 12 h of post-transfection presenting the highest value (figure 3e; electronic supplementary material, table S3). Hence, the upregulation of the persistence of the motor-driven anterograde and retrograde mitochondrial transport by KBD are also tightly coupled processes.
Finally, we examined the mean and absolute anterograde velocities of mitochondrial motile events (figure 4a,b). The former value reflects the average velocity of all motile events recorded in 121 frames, whereas the latter is the velocity of every run (table 1). The absolute velocity correlates directly with the absolute ATPase motor activity of kinesin or the cooperation of multiple motors coupled to the same mitochondrion causing an increase of its net displacement (table 1). Notably, the mean anterograde velocity of mitochondria in KBD-transfected cells (M = 0.5 µm s−1, interquartile range, IQR = 0.43–0.61 µm s−1) became significantly higher only after 12 h of transfection compared with KBD* (M = 0.42 µm s−1, IQR = 0.38–0.46 µm s−1; p ≤ 4.05 × 10−6) and mock-transfected cells (M = 0.43 µm s−1, IQR = 0.37–0.47 µm s−1; p ≤ 1.1 × 10−7; figure 4a; electronic supplementary material, table S1). Likewise, runs with high absolute velocity peaks were detected only at 12 h in the presence of KBD with the highest value recorded at 3.8 µm s−1 (figure 4b; electronic supplementary material, table S2). Thus, the time-dependent expression of KBD promotes the time-dependent upregulation of motor-driven mitochondrial transport by kinesin-1. In addition to the anterograde motility parameters described, we also analysed the effects of KBD on other complementary biophysical events (e.g. displacement), and retrograde and total (anterograde and retrograde) motility-related events (see electronic supplementary material, figure S1b–l). We observed similar outcomes in all retrograde events as for those described for the anterograde events with KBD, and these were indistinguishable between KBD* and mock-transfected cells. Moreover, there were no statistical differences between any anterograde and retrograde motility-related events examined. These data further support that mitochondrial motility events of opposite polarity undergo tight mechanotransduction coupling.
3.4. Wild-type and Ran-GTP-binding deficient constructs of R2KR3 cause the downregulation of mitochondrial kinetics
We then examined the effects of wild-type R2KR3 and counterpart constructs with the W → R mutation in either RBD2 or RBD3 or both ( ) in mitochondrial motility as soon as the expression constructs were detected by CCD imaging-coupled epifluorescence microscopy. Notably, we observed a drastic reduction in mitochondrial motile events after R2KR3 transfection and irrespective of the presence or absence of the W → R mutation(s), which we showed previously to disrupt binding to Ran-GTP (p ≤ 3.5 × 10−4; figure 5a; electronic supplementary material, table S1). Although we observed an increase in mitochondrial motile events in R2KR3-transfected cells between 12 and 15 h of transfection, the mitochondrial motility of mock-transfected cells also showed a significant increase (figure 5a; electronic supplementary material, table S1). Thus, we conclude that the increase in the motile events at 15 h of post-transfection is a secondary effect not attributed to any R2KR3 construct. The effects of R2KR3 constructs on mitochondrial motility suppression were corroborated also by an increase in stationary events and a decrease in their total anterograde displacement (see electronic supplementary material, figure S2a,b) and an increase in the duration of pauses between any R2KR3 constructs and mock-transfected cells (p ≤ 4.7 × 10−4; figure 5b; electronic supplementary material, table S2). They were also accompanied by a significant reduction in the frequency of mitochondrial change in direction when compared with non-transfected cells at all transfection times (p ≤ 1.1 × 10−5; figure 5c; electronic supplementary material, table S1). Hence, these data support that R2KR3 and mutant constructs thereof suppress strongly the overall motility of mitochondria in either direction. Then, we examined the persistence of anterograde motility in the pool of motile mitochondria. There were no significant differences in motility persistence among any R2KR3 constructs (chi-squared contingency test, p > 0.05, χ2 = 20.92), nor did any R2KR3 constructs show anterograde motility persistence contingent upon the time of transfection (chi-squared contingency test, p > 0.05; figure 5d; electronic supplementary material, table S3). Likewise, similar observations were found for persistence in retrograde motility (see electronic supplementary material, figure S2i). However, we found that there was a reduction in the persistence of total mitochondrial motility, an effect that was contingent upon transfection with any R2KR3 construct (chi-squared contingency test, p < 0.001, χ2 = 63.49, Cramer's contingency coefficient ϕ = 0.32; electronic supplementary material, figure S2j). Hence, R2KR3 and mutant constructs thereof promote the downregulation of motor-driven mitochondrial transport.
Finally, we examined the effect of the R2KR3 constructs on the average anterograde velocities of motile events (figure 6a). Mitochondria of R2KR3- and -transfected cells showed significantly higher average anterograde velocity (R2KR3: M = 0.47 µm s−1, IQR = 0.40–0.59 µm s−1; : M = 0.43 µm s−1, IQR = 0.38–0.53 µm s−1) than mock-transfected cells at 12 but not 15 h after transfection (p ≤ 1.2 × 10−5; figure 6a). Notably, there was stereochemical (position dependent) discrimination between the equivalent W2052R and W2349R mutations in the structurally equivalent RBD2 and RBD3 domains, respectively, because only constructs with the W2052R mutation in RBD2 suppress the transient effect of the increased average anterograde velocity of mitochondria observed with other constructs at 12 h (figure 6a). Finally, we observed similar outcomes in all retrograde events as for those described for the anterograde events and on other complementary biophysical events with R2KR3 constructs (see electronic supplementary material, figure S2c–h,k–l).
3.5. Stereochemical control of mitochondrial kinetics by R2KR3
Although there were significant differences in the average anterograde velocity of mitochondria in the presence of R2KR3 or at 12 h post-transfection compared with R*2KR*3 and mock-transfected cells, we observed no significant differences in their absolute anterograde run velocities (data not shown). Hence, to understand the apparent discrepancy between the average and absolute velocities, we examined sparkline plots that show the absolute velocity of every individual run. Notably, we observed an increased number of independent runs with high velocities when R2KR3 constructs contained the wild-type RBD2 domain (figure 6b). Hence, we hypothesized that the high frequency of lower-velocity runs masked less frequent high-velocity runs. To test this hypothesis, we divided the absolute run velocities in two independent populations (those with velocities of less than 0.75 and greater than or equal to 0.75 µm s−1) and analysed the two groups for statistical differences. Indeed, the dot-box plot analysis of absolute velocities greater than or equal to 0.75 µm s−1 showed significant increases in the run velocities of any R2KR3 construct containing the wild-type RBD2 (R2KR3, ), but not the mutant RBD2 ( ) or with mock-transfected cells (figure 6c; electronic supplementary material, table S2). Collectively, these data support transient, non-equivalent, and stereochemical (position)-dependent functional roles of structurally equivalent RBD2 and RBD3 of RanBP2 in the regulation of kinesin-1-mediated mitochondrial motility.
3.6. Distinct functional subdomains are likely to be present across other Ran GTPase-binding domains of RanBP2
The data presented so far strongly support that the RBD2 and RBD3 of RanBP2 harbour mutually exclusive structural and functional subdomains towards Ran-GTP and kinesin-1. These data are also in concordance with our prior studies, where RanBP2 was found to co-associate with KIF5B and KIF5C and Ran GTPase in brain and retinal extracts [23]. Prior structural studies have shown that RBDn = 1–4 present a PH domain fold, which is a highly versatile fold for protein–protein and protein–phosphatidylinositol lipid interactions [4,12]. Further, structural studies on binary complexes of RBD1-Ran-GTP or RanBP1 and RanBP3 within other structural ensembles support the presence of structural subdomains across all RBDn = 1–4 that are exposed to solvent and thus free to participate in interactions with other partners (figure 7a) [4,11,71]. This notion is also supported by the findings that the RBD2 and RBD3, and RBD4, of RanBP2 interact directly with distinct partners, as shown by this and other studies [43–45]. Hence, we searched databases for pathological mutations reported in any RBDn = 1–4 of RanBP2 that would further strengthen the notion of the presence of multi-functional and Ran GTPase-independent activities linked to novel subdomains of RBDn = 1–4. We found a human mutation in the RBD4 of RanBP2, M2965I, which is reported to occur in 83 per cent of pancreatic cancers (figure 7b) [72]. Molecular modelling and overlay structures of all four RBDn = 1–4 of RanBP2 clearly show that the non-conserved M2965 residue is fully exposed to the solvent in a poorly conserved structural loop between the β2 and β3 sheets of RBD4, and away from the W → R substitution in the conserved ‘WKER’ motif (figure 7b) [4]. This clearly shows that the non-conserved M2965 residue does not participate in the interaction with Ran-GTP.
4. Discussion
These studies uncover the presence of novel subdomains in RBD2 and RBD3 of RanBP2 that are critical to kinesin-1 activation, and present non-overlapping structural and functional discrimination between Ran-GTP and kinesin-1 association. In addition, our studies uncover several kinetic properties of regulation of kinesin-1 activation, and establish direct corollaries between biochemical outcomes of single-molecule kinesin activities and the regulation of kinesin-1-mediated mitochondrial motility by KBD, R2KR3 or subdomains thereof of RanBP2. Several important conclusions can be drawn from these studies.
First, the RBD2 and RBD3 of RanBP2 present Ran-GTP-independent functions in kinesin-1 activation. The RBD2 and RBD3 present mutually exclusive interaction sites towards Ran-GTP and kinesin-1 that confer multi-functional properties to these domains. Further, we show that it is possible to dissect kinetically apart the sigmoid (cooperative) and hyperbolic phases of kinesin-1 activation by suppressing the latter upon introduction of the structurally equivalent mutation, W → R, in the conserved ‘WKER’ motifs of RBD2 and RBD3 of R2KR3. Thus, in addition to impairing Ran-GTP association to the RBDs, the W → R substitution also affects a nearby kinesin-interacting subdomain. These observations support that the hyperbolic and sigmoid (cooperative) phases of kinesin-1 activation are not fully interdependent, because the catalytic efficiencies of kinesin-1 upon R2KR3 and stimulations are comparable. Thus, kinesin-1 presents a multi-modal modus operandi by which the initial hyperbolic phase of kinesin motor activity can be bypassed. This activation phase of kinesin was thought previously to be required to ‘jump start’ the motor activity of kinesin-1 [45]. Further, these data strengthen the findings supporting the presence of two tightly conformational coupled sites for the binding of RBD2 and RBD3, and KBD, in R2KR3 to kinesin-1 [45]. Future structural studies with ternary or binary complexes of Ran-GTP-R2KR3-KIF5B/KIF5C or R2KR3-KIF5B/KIF5C should provide additional insights into the mechanisms governing the interactions of R2KR3 with Ran-GTP and KIF5B/KIF5C.
Second, the data reveal two sharply contrasting biological effects of KBD alone and the tripartite domain, R2KR3, on kinesin-1-mediated mitochondrial motility. KBD promotes mitochondrial motility, whereas R2KR3 strongly suppresses such activity regardless of the mutations inhibiting Ran GTPase association to the RBD2 and RBD3 of R2KR3. These effects probably reflect distinct biochemical activities linked to KBD alone, which jump-starts kinesin activation (hyperbolic phase), and those linked to the domains RBD2 and RBD3 of R2KR3, that boost the motor activity of kinesin-1 (cooperative phase) [45]. The results support a model whereby KBD expression leads to the partial and weak occupancy of a cargo-binding site in the multi-partite cargo-binding domain of the tail of kinesin-1 [45]. This leads to the generation of a metastable and partially active form of kinesin-1. We propose that this metastable form of kinesin-1 is highly receptive to engage with its endogenous cargo (mitochondrion) and thus promote an increase in mitochondrial motility as observed upon KBD expression (figure 8a). By contrast, R2KR3 strongly and stably associates with kinesin-1, an effect that reflects its maximal activation of kinesin-1 in vitro (figure 1) [45]. However, the stable association of R2KR3 with kinesin-1 causes its full activation by the complete occupancy of all cargo-binding sites in the multi-partite cargo-binding domain of the tail of kinesin-1 by R2KR3 [45]. The outcome of this effect is the suppression of kinesin-1 engagement with its endogenous cargo (e.g. mitochondrion) in vivo, and thus a sharp decline in mitochondrial motility observed upon R2KR3 expression (figure 8b).
Third, it was revealing that there were temporal and contrasting effects of KBD alone and R2KR3 on the average and absolute velocities of mitochondria. The latency of the KBD effect in the time-dependent upregulation of mitochondrial velocities (e.g. 8–10 versus 12 h) suggests that such an effect is probably caused by the time-dependent increase in KBD expression, which in turn promotes kinesin-1-mediated mitochondrial motility. The low transfection efficiency of the cells with the RanBP2 mini-constructs prevented us from probing this issue further. However, our data strongly support the notion that the increased pool of metastable kinesin-1 produced by an increase in KBD expression promotes the coupling of several kinesin molecules to a mitochondrion, an effect that secondarily leads to an increase in the net displacement of kinesin per molecule of ATP hydrolysed without affecting its ATP turnover rate. Such a mechanism is in line with other studies proposing that the mechanical coupling of a kinesin motor ensemble comprising multiple kinesin motors attached to the same cargo results in an increase in cooperation and net displacement of the kinesin-1 ensemble [73–76]. This mechanism also explains apparent discrepancies of absolute velocities observed between single-molecule and organelle transport studies [77–79]. However, the effect of the copy number of motors engaged with a cargo on its travel velocities is challenged by studies of the transport of lipid droplets by kinesin-1 [80]. The reasons for these apparent discrepancies are unclear, but they may arise from the nature of cargoes, higher regulatory mechanisms on kinesin-1, or both [80,81].
Fourth, the initial but temporary increase in mitochondrial velocity by R2KR3 or , but not or of the pool of mitochondria remaining still motile, supports a stereochemical (position-dependent) effect between the structurally equivalent RBD2 and RBD3 in the modulation of mitochondrial velocity in vivo. This observation suggests that the parallel or anti-parallel interaction of the coiled-coil structure (e.g. heptad leucine repeats) of KBD with the coiled-coil tail domain of kinesin-1 [24] determines non-equivalent and position-dependent effects between RBD2 and RBD3 in the regulation of kinesin-1-mediated mitochondrial velocity. Further, the position-dependent regulatory effect of RBD2 on mitochondrial velocity may be affected also by competitive mechanisms between RBD2 and other endogenous adaptors thought to couple kinesin-1 to the mitochondrion or regulate kinesin-1 stiffness [74,77]. For example, the multi-partite cargo-binding sites in kinesin-1 tail towards R2K domains of R2KR3 compared with KR3 overlap more with its kinesin light chain (KLC)-binding site [24,82], a kinesin-1 adaptor known to associate with mitochondria [83]. Other mammalian factors linking the mitochondrion directly to kinesin-1, such as Miro-1, may compete also with R2KR3 of RanBP2 or have a spatially constrained role in selective subcellular compartments, because in dendrites, Miro-1 regulates the balance between the motile and stationary phases of mitochondria, but apparently without affecting the mitochondrial average velocity [84].
Fifth, our data add to reports indicating that a tight mechanotransduction coupling mechanism operates between kinesin and dynein motors, because impairments in anterograde transport produce similar impairments in retrograde transport of mitochondria [78,85–87]. Indeed, we observed that every transport parameter recorded in one direction was accompanied by changes of opposite vectorial polarity. The notion of a tight mechanotransduction coupling mechanism between two distinct motors gains further strength with the finding that KBD of RanBP2 also binds directly to the C-terminal cargo-binding domain of the mammalian bicaudal D2 (BICD2) [25]. BICD2 acts as a dual adaptor for dynein and kinesin-1, and the competitive or cooperative interplay between these antagonizing motors, BICD2 and RanBP2, regulates the attachment of centrosomes to the nuclear envelope prior to mitotic entry [25], a mechanical checkpoint critical for the motor-driven breakdown of the nuclear envelope during late G2/early prophase [29,30]. Interestingly, other disparate mechanotransduction roles are emerging between RanBP2 and kinesin-1. For example, the activation of kinesin-1 by RanBP2 mediates adenoviral infection by promoting viral capsid disruption and uncoating at the nuclear pore and outward dispersion of capsid and selective nucleoporins, such as RanBP2 [27]. Collectively, these data support that RanBP2 mediates the tight coordination of pleiotropic motor and energy-driven trafficking processes at distinct cell cycles and between various cell types [24,25,27,88]. Future studies on the physiological effects of RBD2, RBD3 and KBD of RanBP2 with animal models should help to tease out the multi-functional activities associated with the interplay between kinesin-1, Ran GTPase and RanBP2 in mitochondrial motility and other transport events.
Finally, our studies uncover that the temporal pauses between mitochondrial runs switching directions are larger than the temporal pauses between runs with similar directions, but the temporal changes between runs switching direction are not affected by any constructs of RanBP2 used. These data support that other mechanisms independent of the constructs used control temporal switches in directionality between motors. In this regard, other factors, such as regulation of phosphatidylinositol (4,5) biphosphate (PtdIns(4,5)P2) signalling in the mitochondria or domains with PtdIns(4,5)P2-binding motifs (pleckstrin homologous), are strong candidates to modulate changes in mitochondrial directionality without impairing the overall levels of mitochondrial motility [89].
In summary, this study uncovers critical Ran-GTP-independent mechanisms modulating biochemical and antagonizing biophysical parameters of fast mitochondrial motility between kinesin-1 and KBD, R2KR3 and subdomains thereof of RanBP2. On the other hand, motor-independent and disparate functions may be associated also with Ran-GTP-independent subdomains of other Ran GTPase-binding domains of RanBP2, such RBD4, which is known to associate with M-opsin, and where the mutation, M2965I, in a non-conserved subdomain, is found in pancreatic cancers (figure 7b) [72]. The role of this mutation in pancreatic function remains unknown. However, it is noteworthy that insufficiency of Ranbp2 is linked to glucose intolerance [35] and metabolic mitochondrial dysfunction [42], whereas kinesin-1 mediates glucose-dependent exocytosis of insulin-containing dense core secretory vesicles in pancreatic β-cells [58,90–92] and transport of glucose transport protein, GLUT4, in adipocytes [93]. It is possible that the metabolic deregulation of these kinesin-1 and RanBP2 activities contributes to the transformation of pancreatic cells. Regardless, the data presented herein open new venues to harness therapeutically multiple motile mechanisms underpinning disparate biological processes in the treatment of a variety of clinical manifestations triggered by the misregulation of microtubule-based motors, RanBP2, mitochondrial motility, or a combination of these.
5. Material and methods
5.1. Protein purification, kinetic analysis of kinesin-1 isoforms and pull-down assays
Full-length human KIF5A, KIF5B, KIF5C and R2KR3 (RBD2–KBD–RBD3), and mutants thereof, were expressed and purified as described elsewhere [45]. Purified recombinant Ran GTPase charged with GppNHp (5′-guanosyl-[β,γ-imido]-triphospahte) was kindly provided by Dr Alfred Wittinghofer. KIF5A, KIF5B, KIF5C were used at 2.5 nM in the kinetic assays. The kinetics of activation (turnover rate, per second) of KIF5A, KIF5B, KIF5C by R2KR3 or mutant constructs thereof were performed by measuring the amount of Pi released with CytoPhos reagent (Cytoskeleton, Inc., Denver, CO) exactly as described previously [45]. Kinetic values were obtained by nonlinear fitting of data using GraphPad (GraphPad Software). For pull-down assays, GST-R2KR3 and were incubated with 50 per cent slurry of glutathione-S1-sepharose 4B (GE) equilibrated with incubation buffer (150 mM NaCl2, 20 mM Tris, 1 mM EDTA, 0.4% NP40, pH 8.0) for 1 h at 24°C, washed three times followed by incubation in the same buffer with Ran-GppNHp for 2 h at 4°C. Sepharose beads were washed three times, and co-precipitates were eluted with Laemmli buffer and resolved by SDS–PAGE. Immunoblots were probed with anti-Ran antibody (1 : 100; Covance, Chantilly, VA).
5.2. Homology modelling of RBDn =2–4 of RanBP2
The stochastic global energy optimization procedure in Internal Coordinate Mechanics v. 3.7–2 (MolSoft, San Diego, CA, USA) [94,95] was used to build models of RBD2, RBD3 and RBD4. The 3.0 Å crystal structure of RBD1 of RanBP2 (PDB code 1RRP) was used as a modelling template, which has the following sequence identity with the query sequence: 59 per cent (RBD2), 51 per cent (RBD3) and 56 per cent (RBD4). The models were refined by globally optimizing the side chains and annealing the backbone using the biased-probability Monte Carlo method [94].
5.3. Cell culture and transient transfections
Mouse NIH/3T3 embryo fibroblasts (ATCC CRL-1658) were grown in Dulbecco's modified Eagle medium (DMEM, Gibco) supplemented with 10 per cent bovine calf serum and 1 per cent antibiotics (Invitrogen) at 37°C in presence of 5 per cent CO2. Upon 70 per cent confluency, cells were plated in 35 mm MatTek glass-bottomed culture dishes (MatTek Co.) for live-cell imaging and tracking studies. After 8 h of platting, the cells were transfected with 1 µg of YFP-KBD, YFP-KBD*, YFP-R2KR3, YFP- or constructs cloned in mammalian expression vector pDest-733Y, using Fugene 6 or X-treamGENE 9 (Roche). KBD* is KBD-Mut1 [24]. Transfection efficiencies for KBD and R2KR3 constructs (and mutant constructs thereof) were 20 per cent and 10 per cent, respectively. Immediately upon expression of KBD constructs (8, 10 or 12 h of post-transfection) and R2KR3 constructs (12 and 15 h of post-transfection), mitochondria of live cells were visualized upon incubation with MitoTracker Red CMXRos (Molecular Probes, no. M-7512) at 19 nM concentration for 30 min at 37°C. The growth medium was replaced by DMEM without serum just prior to live-cell imaging and time-lapse microscopy.
5.4. Time-lapse microscopy and image acquisitions
For live-cell imaging microscopy, culture dishes with transfected and stained mitochondria cells were placed into an integrated LiveCell System Chamber (Pathology Devices) in a controlled environment of 100 per cent humidity, 5 per cent CO2 and at 37°C. The live cell chamber was placed on a Nikon TE2000U microscope stage with a heated Plan Apochromat 60× objective lens (NA of 1.40). Images were acquired for 100 ms at 500 ms intervals for 1 minute (total of 121 fpm) by epifluoresence microscopy with Metamorph v. 6.3 software (Molecular Devices). Photobleaching and phototoxicity were prevented by shuttering the illumination fluorescence pathway with a filter wheel, and applying low exposure and reduced total recording times. Images were captured at non-saturating integration levels and 14-bit mono black/white with a high-quantum efficiency and sensitive CCD camera (Cascade 512K; Roper Scientific) mounted on a Nikon TE2000U microscope (Tokyo, Japan) equipped with appropriate excitation and emission filter wheels (Sutter Instruments, Novato, CA), 120 W mercury light source and an encoded motorized Z-Stage (Prior Scientific).
5.5. Mitochondrial tracking
Images for each dataset were collected from multiple cells in 6 to 12 culture dishes. Each mitochondrion trajectory was tracked and defined with the multi-dimensional, single-particle tracking and motion analysis modules of Metamorph v. 7.7.2.0. In line with other studies, the nucleus was used as a fixed reference point to establish mitochondrial directionality with the anterograde and retrograde motilities pointing away and towards the nucleus. x–y coordinates of a centroid were determined for each mitochondrion at every time point from time stacks composed of 121 frames. Briefly, mitochondrion tracking was aborted when (i) centroid intensity decreased by 40 per cent from the initial frame, (ii) fusion or collision between mitochondria occurred to exclude fusion and fission mitochondrial events, and (iii) the tracked mitochondria disappears from any frame during its trajectory. x–y coordinates of each mitochondrion trajectory were computed, and the data were automatically logged into Excel spreadsheets (Microsoft).
5.6. Data and statistical analyses
Motility profiles for each tracked mitochondrion were generated for each data group comprising approximately 100 mitochondria. All data points were analysed and processed for multiple biophysical parameters (see electronic supplementary material) with a customized batch-processing program developed by the Ferreira Laboratory using Origin v. 8.5 software (Northampton, MA), and that is available upon request. The five statistical parameters summarizing the datasets examined are provided in the electronic supplementary material (tables S1 and S2). Data for all the parameters examined were first tested for normality using the Shapiro–Wilk normality test (α = 0.05). Because none of the parameters examined were normally distributed (data not shown), the non-parametric Kruskal–Wallis test for group analysis and the Mann–Whitney U-test for two group comparisons were used at α = 0.001. Differences in medians were compared using Mood's median test at α = 0.01. The persistency of mitochondrial motility was assessed by chi-squared contingency test, whereas the degree of contingency was measured by Cramer's contingency coefficient (ϕ).
6. Acknowledgements
We thank Dr Alfred Wittinghofer for providing purified recombinant Ran GTPase charged with GppNHp, and Erin Haser and Tomas Moreno for the help with the pilot studies on mitochondrial motility. This work was supported by NIH grants GM083165, EY019492, 2P30-EY005722 and Research to Prevent Blindness to PAF. P.A.F. is the Jules & Doris Stein Research to Prevent Blindness Professor.
Supplementary Material
References
- 1.Izaurralde E, Kutay U, von Kobbe C, Mattaj IW, Gorlich D. 1997. The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. EMBO J. 16, 6535–6547 10.1093/emboj/16.21.6535 (doi:10.1093/emboj/16.21.6535) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bischoff FR, Krebber H, Smirnova E, Dong W, Ponstingl H. 1995. Co-activation of RanGTPase and inhibition of GTP dissociation by Ran-GTP binding protein RanBP1. EMBO J. 14, 705–715 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Villa Braslavsky CI, Nowak C, Gorlich D, Wittinghofer A, Kuhlmann J. 2000. Different structural and kinetic requirements for the interaction of Ran with the Ran-binding domains from RanBP2 and importin-beta. Biochemistry 39, 11 629–11 639 10.1021/bi001010f (doi:10.1021/bi001010f) [DOI] [PubMed] [Google Scholar]
- 4.Vetter IR, Nowak C, Nishimoto T, Kuhlmann J, Wittinghofer A. 1999. Structure of a Ran-binding domain complexed with Ran bound to a GTP analogue: implications for nuclear transport. Nature 398, 39–46 10.1038/17969 (doi:10.1038/17969) [DOI] [PubMed] [Google Scholar]
- 5.Richards SA, Lounsbury KM, Carey KL, Macara IG. 1996. A nuclear export signal is essential for the cytosolic localization of the Ran binding protein, RanBP1. J. Cell Biol. 134, 1157–1168 10.1083/jcb.134.5.1157 (doi:10.1083/jcb.134.5.1157) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Coutavas E, Ren M, Oppenheim JD, D'Eustachio P, Rush MG. 1993. Characterization of proteins that interact with the cell-cycle regulatory protein Ran/TC4. Nature 366, 585–587 10.1038/366585a0 (doi:10.1038/366585a0) [DOI] [PubMed] [Google Scholar]
- 7.Wu J, Matunis MJ, Kraemer D, Blobel G, Coutavas E. 1995. Nup358, a cytoplasmically exposed nucleoporin with peptide repeats, Ran-GTP binding sites, zinc fingers, a cyclophilin A homologous domain, and a leucine-rich region. J. Biol. Chem. 270, 14 209–14 213 10.1074/jbc.270.23.14209 (doi:10.1074/jbc.270.23.14209) [DOI] [PubMed] [Google Scholar]
- 8.Yokoyama N, et al. 1995. A giant nucleopore protein that binds Ran/TC4. Nature 376, 184–188 10.1038/376184a0 (doi:10.1038/376184a0) [DOI] [PubMed] [Google Scholar]
- 9.Ferreira PA, Hom JT, Pak WL. 1995. Retina-specifically expressed novel subtypes of bovine cyclophilin. J. Biol. Chem. 270, 23 179–23 188 10.1074/jbc.270.39.23179 (doi:10.1074/jbc.270.39.23179) [DOI] [PubMed] [Google Scholar]
- 10.Seewald MJ, Korner C, Wittinghofer A, Vetter IR. 2002. RanGAP mediates GTP hydrolysis without an arginine finger. Nature 415, 662–666 10.1038/415662a (doi:10.1038/415662a) [DOI] [PubMed] [Google Scholar]
- 11.Koyama M, Matsuura Y. 2010. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J. 29, 2002–2013 10.1038/emboj.2010.89 (doi:10.1038/emboj.2010.89) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.van Rossum DB, Patterson RL, Sharma S, Barrow RK, Kornberg M, Gill DL, Snyder SH. 2005. Phospholipase Cgamma1 controls surface expression of TRPC3 through an intermolecular PH domain. Nature 434, 99–104 10.1038/nature03340 (doi:10.1038/nature03340) [DOI] [PubMed] [Google Scholar]
- 13.Delphin C, Guan T, Melchior F, Gerace L. 1997. RanGTP targets p97 to RanBP2, a filamentous protein localized at the cytoplasmic periphery of the nuclear pore complex. Mol. Biol. Cell 8, 2379–2390 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Singh BB, Patel HH, Roepman R, Schick D, Ferreira PA. 1999. The zinc finger cluster domain of RanBP2 is a specific docking site for the nuclear export factor, exportin-1. J. Biol. Chem. 274, 37 370–37 378 10.1074/jbc.274.52.37370 (doi:10.1074/jbc.274.52.37370) [DOI] [PubMed] [Google Scholar]
- 15.Bischoff FR, Klebe C, Kretschmer J, Wittinghofer A, Ponstingl H. 1994. RanGAP1 induces GTPase activity of nuclear Ras-related Ran. Proc. Natl Acad. Sci. USA 91, 2587–2591 10.1073/pnas.91.7.2587 (doi:10.1073/pnas.91.7.2587) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. 1997. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88, 97–107 10.1016/S0092-8674(00)81862-0 (doi:10.1016/S0092-8674(00)81862-0) [DOI] [PubMed] [Google Scholar]
- 17.Matunis MJ, Coutavas E, Blobel G. 1996. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 135, 1457–1470 10.1083/jcb.135.6.1457 (doi:10.1083/jcb.135.6.1457) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Bernad R, van der Velde H, Fornerod M, Pickersgill H. 2004. Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. Mol. Cell Biol. 24, 2373–2384 10.1128/MCB.24.6.2373-2384.2004 (doi:10.1128/MCB.24.6.2373-2384.2004) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Engelsma D, Bernad R, Calafat J, Fornerod M. 2004. Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358. EMBO J. 23, 3643–3652 10.1038/sj.emboj.7600370 (doi:10.1038/sj.emboj.7600370) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Forler D, Rabut G, Ciccarelli FD, Herold A, Kocher T, Niggeweg R, Bork P, Ellenberg J, Izaurralde E. 2004. RanBP2/Nup358 provides a major binding site for NXF1-p15 dimers at the nuclear pore complex and functions in nuclear mRNA export. Mol. Cell Biol. 24, 1155–1167 10.1128/MCB.24.3.1155-1167.2004 (doi:10.1128/MCB.24.3.1155-1167.2004) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hutten S, Walde S, Spillner C, Hauber J, Kehlenbach RH. 2009. The nuclear pore component Nup358 promotes transportin-dependent nuclear import. J. Cell Sci. 122, 1100–1110 10.1242/jcs.040154 (doi:10.1242/jcs.040154) [DOI] [PubMed] [Google Scholar]
- 22.Hamada M, Haeger A, Jeganathan KB, van Ree JH, Malureanu L, Walde S, Joseph J, Kehlenbach RH, van Deursen JM. 2011. Ran-dependent docking of importin-beta to RanBP2/Nup358 filaments is essential for protein import and cell viability. J. Cell Biol. 194, 597–612 10.1083/jcb.201102018 (doi:10.1083/jcb.201102018) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Cai Y, Singh BB, Aslanukov A, Zhao H, Ferreira PA. 2001. The docking of kinesins, KIF5B and KIF5C, to Ran-binding protein 2 (RanBP2) is mediated via a novel RanBP2 domain. J. Biol. Chem. 276, 41 594–41 602 10.1074/jbc.M104514200 (doi:10.1074/jbc.M104514200) [DOI] [PubMed] [Google Scholar]
- 24.Cho KI, Cai Y, Yi H, Yeh A, Aslanukov A, Ferreira PA. 2007. Association of the kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria localization and function. Traffic 8, 1722–1735 10.1111/j.1600-0854.2007.00647.x (doi:10.1111/j.1600-0854.2007.00647.x) [DOI] [PubMed] [Google Scholar]
- 25.Splinter D, et al. 2010. Bicaudal D2, dynein, and kinesin-1 associate with nuclear pore complexes and regulate centrosome and nuclear positioning during mitotic entry. PLoS Biol. 8, e1000350. 10.1371/journal.pbio.1000350 (doi:10.1371/journal.pbio.1000350) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Joseph J, Dasso M. 2008. The nucleoporin Nup358 associates with and regulates interphase microtubules. FEBS Lett. 582, 190–196 10.1016/j.febslet.2007.11.087 (doi:10.1016/j.febslet.2007.11.087) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Strunze S, et al. 2011. Kinesin-1-mediated capsid disassembly and disruption of the nuclear pore complex promote virus infection. Cell Host Microbe 10, 210–223 10.1016/j.chom.2011.08.010 (doi:10.1016/j.chom.2011.08.010) [DOI] [PubMed] [Google Scholar]
- 28.Zhang R, Mehla R, Chauhan A. 2010. Perturbation of host nuclear membrane component RanBP2 impairs the nuclear import of human immunodeficiency virus -1 preintegration complex (DNA). PLoS ONE 5, e15620. 10.1371/journal.pone.0015620 (doi:10.1371/journal.pone.0015620) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Prunuske AJ, Liu J, Elgort S, Joseph J, Dasso M, Ullman KS. 2006. Nuclear envelope breakdown is coordinated by both Nup358/RanBP2 and Nup153, two nucleoporins with zinc finger modules. Mol. Biol. Cell 17, 760–769 10.1091/mbc.E05-06-0485 (doi:10.1091/mbc.E05-06-0485) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Salina D, Enarson P, Rattner JB, Burke B. 2003. Nup358 integrates nuclear envelope breakdown with kinetochore assembly. J. Cell Biol. 162, 991–1001 10.1083/jcb.200304080 (doi:10.1083/jcb.200304080) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Klein UR, Haindl M, Nigg EA, Muller S. 2009. RanBP2 and SENP3 function in a mitotic SUMO2/3 conjugation–deconjugation cycle on Borealin. Mol. Biol. Cell 20, 410–418 10.1091/mbc.E08-05-0511 (doi:10.1091/mbc.E08-05-0511) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Dawlaty MM, Malureanu L, Jeganathan KB, Kao E, Sustmann C, Tahk S, Shuai K, Grosschedl R, van Deursen JM. 2008. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 133, 103–115 10.1016/j.cell.2008.01.045 (doi:10.1016/j.cell.2008.01.045) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Ferreira PA, Yunfei C, Schick D, Roepman R. 1998. The cyclophilin-like domain mediates the association of Ran-binding protein 2 with subunits of the 19 S regulatory complex of the proteasome. J. Biol. Chem. 273, 24 676–24 682 10.1074/jbc.273.38.24676 (doi:10.1074/jbc.273.38.24676) [DOI] [PubMed] [Google Scholar]
- 34.Yi H, Friedman JL, Ferreira PA. 2007. The cyclophilin-like domain of Ran-binding protein-2 modulates selectively the activity of the ubiquitin-proteasome system and protein biogenesis. J. Biol. Chem. 282, 34 770–34 778 10.1074/jbc.M706903200 (doi:10.1074/jbc.M706903200) [DOI] [PubMed] [Google Scholar]
- 35.Aslanukov A, et al. 2006. RanBP2 modulates Cox11 and hexokinase i activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism. PLoS Genet. 2, e177. 10.1371/journal.pgen.0020177 (doi:10.1371/journal.pgen.0020177) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Pichler A, Gast A, Seeler JS, Dejean A, Melchior F. 2002. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108, 109–120 10.1016/S0092-8674(01)00633-X (doi:10.1016/S0092-8674(01)00633-X) [DOI] [PubMed] [Google Scholar]
- 37.Zhang H, Saitoh H, Matunis MJ. 2002. Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol. Cell Biol. 22, 6498–6508 10.1128/MCB.22.18.6498-6508.2002 (doi:10.1128/MCB.22.18.6498-6508.2002) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Werner A, Flotho A, Melchior F. 2012. The RanBP2/RanGAP1(*)SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol. Cell 46, 287–298 10.1016/j.molcel.2012.02.017 (doi:10.1016/j.molcel.2012.02.017) [DOI] [PubMed] [Google Scholar]
- 39.Gloerich M, Vliem MJ, Prummel E, Meijer LA, Rensen MG, Rehmann H, Bos JL. 2011. The nucleoporin RanBP2 tethers the cAMP effector Epac1 and inhibits its catalytic activity. J. Cell Biol. 193, 1009–1020 10.1083/jcb.201011126 (doi:10.1083/jcb.201011126) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Cho KI, Yi H, Yeh A, Tserentsoodol N, Cuadrado L, Searle K, Hao Y, Ferreira PA. 2009. Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons. Cell Death Differ. 16, 287–297 10.1038/cdd.2008.153 (doi:10.1038/cdd.2008.153) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Cho KI, Yi H, Tserentsoodol N, Searle K, Ferreira PA. 2010. Neuroprotection resulting from insufficiency of RANBP2 is associated with the modulation of protein and lipid homeostasis of functionally diverse but linked pathways in response to oxidative stress. Dis. Models Mech. 3, 595–604 10.1242/dmm.004648 (doi:10.1242/dmm.004648) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Cho KI, Searle K, Webb M, Yi H, Ferreira PA. 2012. Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Cell. Mol. Life Sci. 69, 3511–3527 10.1007/s00018-012-1071-9 (doi:10.1007/s00018-012-1071-9) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Ferreira PA, Nakayama TA, Pak WL, Travis GH. 1996. Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin. Nature 383, 637–640 10.1038/383637a0 (doi:10.1038/383637a0) [DOI] [PubMed] [Google Scholar]
- 44.Ferreira PA, Nakayama TA, Travis GH. 1997. Interconversion of red opsin isoforms by the cyclophilin-related chaperone protein Ran-binding protein 2. Proc. Natl Acad. Sci. USA 94, 1556–1561 10.1073/pnas.94.4.1556 (doi:10.1073/pnas.94.4.1556) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Cho KI, Yi H, Desai R, Hand AR, Haas AL, Ferreira PA. 2009. RANBP2 is an allosteric activator of the conventional kinesin-1 motor protein, KIF5B, in a minimal cell-free system. EMBO Rep. 10, 480–486 10.1038/embor.2009.29 (doi:10.1038/embor.2009.29) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Adio S, Reth J, Bathe F, Woehlke G. 2006. Review: regulation mechanisms of Kinesin-1. J. Muscle Res. Cell Motil. 27, 153–160 10.1007/s10974-005-9054-1 (doi:10.1007/s10974-005-9054-1) [DOI] [PubMed] [Google Scholar]
- 47.Gindhart JG. 2006. Towards an understanding of kinesin-1 dependent transport pathways through the study of protein-protein interactions. Brief. Funct. Genomics 5, 74–86 10.1093/bfgp/ell002 (doi:10.1093/bfgp/ell002) [DOI] [PubMed] [Google Scholar]
- 48.Hirokawa N, Noda Y, Tanaka Y, Niwa S. 2009. Kinesin superfamily motor proteins and intracellular transport. Nat. Rev. Mol. Cell Biol. 10, 682–696 10.1038/nrm2774 (doi:10.1038/nrm2774) [DOI] [PubMed] [Google Scholar]
- 49.Pilling AD, Horiuchi D, Lively CM, Saxton WM. 2006. Kinesin-1 and dynein are the primary motors for fast transport of mitochondria in Drosophila motor axons. Mol. Biol. Cell 17, 2057–2068 10.1091/mbc.E05-06-0526 (doi:10.1091/mbc.E05-06-0526) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Kanai Y, Okada Y, Tanaka Y, Harada A, Terada S, Hirokawa N. 2000. KIF5C, a novel neuronal kinesin enriched in motor neurons. J. Neurosci. 20, 6374–6384 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Tanaka Y, Kanai Y, Okada Y, Nonaka S, Takeda S, Harada A, Hirokawa N. 1998. Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria. Cell 93, 1147–1158 10.1016/S0092-8674(00)81459-2 (doi:10.1016/S0092-8674(00)81459-2) [DOI] [PubMed] [Google Scholar]
- 52.Rodionov VI, Gyoeva FK, Tanaka E, Bershadsky AD, Vasiliev JM, Gelfand VI. 1993. Microtubule-dependent control of cell shape and pseudopodial activity is inhibited by the antibody to kinesin motor domain. J. Cell Biol. 123, 1811–1820 10.1083/jcb.123.6.1811 (doi:10.1083/jcb.123.6.1811) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Leopold PL, McDowall AW, Pfister KK, Bloom GS, Brady ST. 1992. Association of kinesin with characterized membrane-bounded organelles. Cell Motil. Cytoskeleton 23, 19–33 10.1002/cm.970230104 (doi:10.1002/cm.970230104) [DOI] [PubMed] [Google Scholar]
- 54.Chang DT, Reynolds IJ. 2006. Mitochondrial trafficking and morphology in healthy and injured neurons. Prog. Neurobiol. 80, 241–268 10.1016/j.pneurobio.2006.09.003 (doi:10.1016/j.pneurobio.2006.09.003) [DOI] [PubMed] [Google Scholar]
- 55.De Vos KJ, Grierson AJ, Ackerley S, Miller CC. 2008. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 31, 151–173 10.1146/annurev.neuro.31.061307.090711 (doi:10.1146/annurev.neuro.31.061307.090711) [DOI] [PubMed] [Google Scholar]
- 56.Liesa M, Palacin M, Zorzano A. 2009. Mitochondrial dynamics in mammalian health and disease. Physiol. Rev. 89, 799–845 10.1152/physrev.00030.2008 (doi:10.1152/physrev.00030.2008) [DOI] [PubMed] [Google Scholar]
- 57.Hirokawa N, Takemura R. 2003. Biochemical and molecular characterization of diseases linked to motor proteins. Trends Biochem. Sci. 28, 558–565 10.1016/j.tibs.2003.08.006 (doi:10.1016/j.tibs.2003.08.006) [DOI] [PubMed] [Google Scholar]
- 58.Cui J, et al. 2011. Targeted inactivation of kinesin-1 in pancreatic beta-cells in vivo leads to insulin secretory deficiency. Diabetes 60, 320–330 10.2337/db09-1078 (doi:10.2337/db09-1078) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Mandelkow E, Mandelkow EM. 2002. Kinesin motors and disease. Trends Cell Biol. 12, 585–591 10.1016/S0962-8924(02)02400-5 (doi:10.1016/S0962-8924(02)02400-5) [DOI] [PubMed] [Google Scholar]
- 60.Learman SS, Kim CD, Stevens NS, Kim S, Wojcik EJ, Walker RA. 2009. NSC. 622124 inhibits human Eg5 and other kinesins via interaction with the conserved microtubule-binding site. Biochemistry 48, 1754–1762 10.1021/bi801291q (doi:10.1021/bi801291q) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Sakowicz R, Berdelis MS, Ray K, Blackburn CL, Hopmann C, Faulkner DJ, Goldstein LS. 1998. A marine natural product inhibitor of kinesin motors. Science 280, 292–295 10.1126/science.280.5361.292 (doi:10.1126/science.280.5361.292) [DOI] [PubMed] [Google Scholar]
- 62.Reddie KG, Roberts DR, Dore TM. 2006. Inhibition of kinesin motor proteins by adociasulfate-2. J. Med. Chem. 49, 4857–4860 10.1021/jm060115z (doi:10.1021/jm060115z) [DOI] [PubMed] [Google Scholar]
- 63.Miyamoto Y, Muto E, Mashimo T, Iwane AH, Yoshiya I, Yanagida T. 2000. Direct inhibition of microtubule-based kinesin motility by local anesthetics. Biophys. J. 78, 940–949 10.1016/S0006-3495(00)76651-3 (doi:10.1016/S0006-3495(00)76651-3) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Reid E, et al. 2002. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet. 71, 1189–1194 10.1086/344210 (doi:10.1086/344210) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Xia CH, Roberts EA, Her LS, Liu X, Williams DS, Cleveland DW, Goldstein LS. 2003. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J. Cell Biol. 161, 55–66 10.1083/jcb.200301026 (doi:10.1083/jcb.200301026) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Allen RD, Metuzals J, Tasaki I, Brady ST, Gilbert SP. 1982. Fast axonal transport in squid giant axon. Science 218, 1127–1129 10.1126/science.6183744 (doi:10.1126/science.6183744) [DOI] [PubMed] [Google Scholar]
- 67.Hollenbeck PJ. 1996. The pattern and mechanism of mitochondrial transport in axons. Front. Biosci. 1, d91–102 [DOI] [PubMed] [Google Scholar]
- 68.Ligon LA, Steward O. 2000. Movement of mitochondria in the axons and dendrites of cultured hippocampal neurons. J. Comp. Neurol. 427, 340–350 (doi:10.1002/1096-9861(20001120)427:3<340::AID-CNE2>3.0.CO;2-Y) [DOI] [PubMed] [Google Scholar]
- 69.Morris RL, Hollenbeck PJ. 1995. Axonal transport of mitochondria along microtubules and F-actin in living vertebrate neurons. J. Cell Biol. 131, 1315–1326 10.1083/jcb.131.5.1315 (doi:10.1083/jcb.131.5.1315) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Kuznetsov SA, Langford GM, Weiss DG. 1992. Actin-dependent organelle movement in squid axoplasm. Nature 356, 722–725 10.1038/356722a0 (doi:10.1038/356722a0) [DOI] [PubMed] [Google Scholar]
- 71.Langer K, Dian C, Rybin V, Muller CW, Petosa C. 2011. Insights into the function of the CRM1 cofactor RanBP3 from the structure of its Ran-binding domain. PLoS ONE 6, e17011. 10.1371/journal.pone.0017011 (doi:10.1371/journal.pone.0017011) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Jones S, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 10.1126/science.1164368 (doi:10.1126/science.1164368) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Gagliano J, Walb M, Blaker B, Macosko JC, Holzwarth G. 2010. Kinesin velocity increases with the number of motors pulling against viscoelastic drag. Eur. Biophys. J. 39, 801–813 10.1007/s00249-009-0560-8 (doi:10.1007/s00249-009-0560-8) [DOI] [PubMed] [Google Scholar]
- 74.Bieling P, Telley IA, Piehler J, Surrey T. 2008. Processive kinesins require loose mechanical coupling for efficient collective motility. EMBO Rep. 9, 1121–1127 10.1038/embor.2008.169 (doi:10.1038/embor.2008.169) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Svoboda K, Block SM. 1994. Force and velocity measured for single kinesin molecules. Cell 77, 773–784 10.1016/0092-8674(94)90060-4 (doi:10.1016/0092-8674(94)90060-4) [DOI] [PubMed] [Google Scholar]
- 76.Levi V, Serpinskaya AS, Gratton E, Gelfand V. 2006. Organelle transport along microtubules in Xenopus melanophores: evidence for cooperation between multiple motors. Biophys. J. 90, 318–327 10.1529/biophysj.105.067843 (doi:10.1529/biophysj.105.067843) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Bruno L, Salierno M, Wetzler DE, Desposito MA, Levi V. 2011. Mechanical properties of organelles driven by microtubule-dependent molecular motors in living cells. PLoS ONE 6, e18332. 10.1371/journal.pone.0018332 (doi:10.1371/journal.pone.0018332) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Brady ST, Pfister KK, Bloom GS. 1990. A monoclonal antibody against kinesin inhibits both anterograde and retrograde fast axonal transport in squid axoplasm. Proc. Natl Acad. Sci. USA 87, 1061–1065 10.1073/pnas.87.3.1061 (doi:10.1073/pnas.87.3.1061) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Dunn S, Morrison EE, Liverpool TB, Molina-Paris C, Cross RA, Alonso MC, Peckham M. 2008. Differential trafficking of Kif5c on tyrosinated and detyrosinated microtubules in live cells. J. Cell Sci. 121, 1085–1095 10.1242/jcs.026492 (doi:10.1242/jcs.026492) [DOI] [PubMed] [Google Scholar]
- 80.Shubeita GT, Tran SL, Xu J, Vershinin M, Cermelli S, Cotton SL, Welte MA, Gross SP. 2008. Consequences of motor copy number on the intracellular transport of kinesin-1-driven lipid droplets. Cell 135, 1098–1107 10.1016/j.cell.2008.10.021 (doi:10.1016/j.cell.2008.10.021) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Morfini GA, et al. 2009. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat. Neurosci. 12, 864–871 10.1038/nn.2346 (doi:10.1038/nn.2346) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Diefenbach RJ, Mackay JP, Armati PJ, Cunningham AL. 1998. The C-terminal region of the stalk domain of ubiquitous human kinesin heavy chain contains the binding site for kinesin light chain. Biochemistry 37, 16 663–16 670 10.1021/bi981163r (doi:10.1021/bi981163r) [DOI] [PubMed] [Google Scholar]
- 83.Khodjakov A, Lizunova EM, Minin AA, Koonce MP, Gyoeva FK. 1998. A specific light chain of kinesin associates with mitochondria in cultured cells. Mol. Biol. Cell 9, 333–343 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Macaskill AF, Rinholm JE, Twelvetrees AE, Arancibia-Carcamo IL, Muir J, Fransson A, Aspenstrom P, Attwell D, Kittler JT. 2009. Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses. Neuron 61, 541–555 10.1016/j.neuron.2009.01.030 (doi:10.1016/j.neuron.2009.01.030) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Ally S, Larson AG, Barlan K, Rice SE, Gelfand VI. 2009. Opposite-polarity motors activate one another to trigger cargo transport in live cells. J. Cell Biol. 187, 1071–1082 10.1083/jcb.200908075 (doi:10.1083/jcb.200908075) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Welte MA. 2010. Bidirectional transport: matchmaking for motors. Curr. Biol. 20, R410–R413 10.1016/j.cub.2010.03.018 (doi:10.1016/j.cub.2010.03.018) [DOI] [PubMed] [Google Scholar]
- 87.Gross SP, Welte MA, Block SM, Wieschaus EF. 2002. Coordination of opposite-polarity microtubule motors. J. Cell Biol. 156, 715–724 10.1083/jcb.200109047 (doi:10.1083/jcb.200109047) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Rundle NT, Nelson J, Flory MR, Joseph J, Th'ng J, Aebersold R, Dasso M, Andersen RJ, Roberge M. 2006. An ent-kaurene that inhibits mitotic chromosome movement and binds the kinetochore protein ran-binding protein 2. ACS Chem. Biol. 1, 443–450 10.1021/cb600196w (doi:10.1021/cb600196w) [DOI] [PubMed] [Google Scholar]
- 89.De Vos KJ, Sable J, Miller KE, Sheetz MP. 2003. Expression of phosphatidylinositol (4,5) bisphosphate-specific pleckstrin homology domains alters direction but not the level of axonal transport of mitochondria. Mol. Biol. Cell 14, 3636–3649 10.1091/mbc.E02-10-0638 (doi:10.1091/mbc.E02-10-0638) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Varadi A, Ainscow EK, Allan VJ, Rutter GA. 2002. Involvement of conventional kinesin in glucose-stimulated secretory granule movements and exocytosis in clonal pancreatic beta-cells. J. Cell Sci. 115, 4177–4189 10.1242/jcs.00083 (doi:10.1242/jcs.00083) [DOI] [PubMed] [Google Scholar]
- 91.Varadi A, Tsuboi T, Johnson-Cadwell LI, Allan VJ, Rutter GA. 2003. Kinesin I and cytoplasmic dynein orchestrate glucose-stimulated insulin-containing vesicle movements in clonal MIN6 beta-cells. Biochem. Biophys. Res. Commun. 311, 272–282 10.1016/j.bbrc.2003.09.208 (doi:10.1016/j.bbrc.2003.09.208) [DOI] [PubMed] [Google Scholar]
- 92.Rutter GA, Hill EV. 2006. Insulin vesicle release: walk, kiss, pause…, then run. Physiology 21, 189–196 10.1152/physiol.00002.2006 (doi:10.1152/physiol.00002.2006) [DOI] [PubMed] [Google Scholar]
- 93.Semiz S, Park JG, Nicoloro SM, Furcinitti P, Zhang C, Chawla A, Leszyk J, Czech MP. 2003. Conventional kinesin KIF5B mediates insulin-stimulated GLUT4 movements on microtubules. EMBO J. 22, 2387–2399 10.1093/emboj/cdg237 (doi:10.1093/emboj/cdg237) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Abagyan R, Totrov M. 1994. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 235, 983–1002 10.1006/jmbi.1994.1052 (doi:10.1006/jmbi.1994.1052) [DOI] [PubMed] [Google Scholar]
- 95.Abagyan R, Totrov M, Kuznetsov D. 1994. ICM-a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 15, 488–506 10.1002/jcc.540150503 (doi:10.1002/jcc.540150503) [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.